• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of emicizumab and other novel agents in newborns and infants.

作者信息

Pierce Glenn F, Hart Daniel P, Kaczmarek Radoslaw

机构信息

Coagulation Products Safety Supply and Access Committee of the World Federation of Hemophilia, Montreal, Québec, Canada.

Barts and The London School of Medicine and Dentistry, Blizard Institute, QMUL, London, UK.

出版信息

Haemophilia. 2019 Sep;25(5):e334-e335. doi: 10.1111/hae.13822. Epub 2019 Jul 30.

DOI:10.1111/hae.13822
PMID:31361382
Abstract
摘要

相似文献

1
Safety and efficacy of emicizumab and other novel agents in newborns and infants.艾美赛珠单抗及其他新型药物在新生儿和婴儿中的安全性与有效性。
Haemophilia. 2019 Sep;25(5):e334-e335. doi: 10.1111/hae.13822. Epub 2019 Jul 30.
2
Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.对一名患有甲型血友病和硬膜下出血的婴儿开始使用emicizumab进行预防治疗。
Haemophilia. 2020 Nov;26(6):e353-e355. doi: 10.1111/hae.14133. Epub 2020 Sep 6.
3
Emicizumab should be prescribed independent of immune tolerance induction.依库珠单抗的使用不应依赖于免疫耐受诱导。
Blood Adv. 2018 Oct 23;2(20):2783-2786. doi: 10.1182/bloodadvances.2018015859.
4
Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies.艾美赛珠单抗治疗伴有同种抗体的 3 型血管性血友病患儿的疗效。
Blood Adv. 2019 Sep 24;3(18):2748-2750. doi: 10.1182/bloodadvances.2019000656.
5
Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment.艾美赛珠单抗对凝血酶生成的影响：一例艾美赛珠单抗治疗期间突破性出血的病例报告。
Haemophilia. 2020 Nov;26(6):e327-e330. doi: 10.1111/hae.14085. Epub 2020 Jun 28.
6
A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement.一名接受emicizumab治疗后出现关节疼痛的男孩：血浆水平测量的重要性。
Haemophilia. 2020 May;26(3):e138-e140. doi: 10.1111/hae.13965. Epub 2020 Apr 16.
7
The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity.凝血因子 VIII 重链可改善艾美赛珠单抗-凝血酶原酶组装，以增强模拟凝血因子 VIII 的辅因子活性。
Thromb Res. 2018 Jun;166:77-79. doi: 10.1016/j.thromres.2018.04.016. Epub 2018 Apr 17.
8
Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.在接受emicizumab预防治疗且无全面凝血监测的甲型血友病和抑制剂患者中的大手术管理
Br J Haematol. 2020 May;189(3):e100-e103. doi: 10.1111/bjh.16512. Epub 2020 Feb 22.
9
Emicizumab-kxwh: First Global Approval.依美珠单抗-kxwh：全球首次获批。
Drugs. 2018 Feb;78(2):269-274. doi: 10.1007/s40265-018-0861-2.
10
Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.依库珠单抗，一种人源化的双特异性抗体，靶向凝血因子 IXa 和 X，同时具有因子 VIIIa 辅因子活性。
Int J Hematol. 2020 Jan;111(1):20-30. doi: 10.1007/s12185-018-2545-9. Epub 2018 Oct 22.

引用本文的文献

1
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.用于预防先天性 A 型或 B 型血友病患者出血的非凝血因子治疗方法。
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2.
2
Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.康西珠单抗作为A型或B型血友病患者的皮下预防治疗选择：证据综述与患者观点
J Blood Med. 2022 Apr 16;13:191-199. doi: 10.2147/JBM.S242219. eCollection 2022.
3
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.
重度甲型血友病无抑制物患者的当前治疗选择与管理：小型德尔菲共识
J Clin Med. 2022 Feb 2;11(3):801. doi: 10.3390/jcm11030801.
4
Disruptive technology and hemophilia care: The multiple impacts of emicizumab.颠覆性技术与血友病护理：艾美赛珠单抗的多重影响
Res Pract Thromb Haemost. 2021 May 7;5(4):e12508. doi: 10.1002/rth2.12508. eCollection 2021 May.
5
Making friends out of foes: novel therapeutic approaches for haemophilia.化敌为友：血友病的新型治疗方法
Blood Transfus. 2021 Mar;19(2):179-180. doi: 10.2450/2020.0403-20. Epub 2020 Dec 23.
6
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.应用血友病死亡率框架对依库珠单抗全球安全数据库进行分析。
J Thromb Haemost. 2021 Jan;19 Suppl 1(Suppl 1):32-41. doi: 10.1111/jth.15187.
7
European principles of inhibitor management in patients with haemophilia: implications of new treatment options.欧洲血友病患者抑制剂管理原则：新治疗选择的影响
Orphanet J Rare Dis. 2020 Aug 24;15(1):219. doi: 10.1186/s13023-020-01511-8.
8
A Molecular Revolution in the Treatment of Hemophilia.血友病治疗的分子革命。
Mol Ther. 2020 Apr 8;28(4):997-1015. doi: 10.1016/j.ymthe.2019.11.006. Epub 2019 Nov 13.